December 7, 2017, SAN ANTONIO – StemBioSys Inc. announced that it has entered into an agreement with Caltag Medsystems Ltd. to distribute and market StemBioSys products. Caltag will distribute StemBioSys products in the European Union.
Initially, the agreement will cover StemBioSys’ cell expansion products, but as additional products are added to StemBioSys’ portfolio in the future, these will likely also be included in the distribution agreement, according to StemBioSys President & CEO Bob Hutchens.
“Europe is one of the leading areas in stem cell research and we are delighted to have the opportunity to expand access to this market though our partnership with Caltag,” Hutchen said. “Caltag is a recognized life science tool company in the UK and across Europe with deep technical expertise. Caltag carries a full range of complementary products and we are very excited to announce them as our new distributor in these markets. Europe has many progressive research institutions and key opinion leaders in stem cell research. Making our novel products readily available to these groups should foster new discoveries in this rapidly progressing field.” he said.
Jill Smith, Chief Operating Officer of Caltag, said, “We are delighted to represent StemBioSys in Europe, and believe this will be a long and fruitful relationship for both companies. The novel StemBioSys product offering complements the cell and tissue range already offered by Caltag Medsystems, allowing a 3D cell culture solution to be delivered to scientists Europe wide”
About Caltag Medsystems Ltd.
Caltag Medsystems based in Buckingham in the UK, supplies research reagents for Cell Biology, Flow Cytometry, Immunology, and Neuroscience in a variety of formats. The Cell and Tissue section of our portfolio includes primary cells, stem cells, cell lines, media, healthy & diseased tissue and cells, angiogenesis models and transfection reagents. The diverse portfolio of products available is a combination of products from a selection of premier suppliers plus our own, in house, manufactured products from the Cellworks and Cytomark brands.
About StemBioSys Inc.
StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful stem cell therapies.